According the Wegovy manufacturer NovoNordisk, the company has stopped shipments of the 0.25 mg and 0.5 mg dose strengths because of supply and manufacturing issues. The company is doing this to lower demand from new patients so that they can help provide the supply for current patients.
Novo Nordisk expects to have all dose strengths by the end of 2022 and have additional production capacity ready in 2023.